Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0HEJWD
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
ABBV-011
|
|||||
| Synonyms |
ABBV-011; SC-011
Click to Show/Hide
|
|||||
| Organization |
Stemcentrx (Top20 MNC) (Originator)
|
|||||
| Drug Status |
Phase 1 (discontinued)
|
|||||
| Drug-to-Antibody Ratio |
2
|
|||||
| Structure |
|
|||||
| Antibody Name |
SC17
|
Antibody Info | ||||
| Antigen Name |
Seizure protein 6 homolog (SEZ6)
|
Antigen Info | ||||
| Payload Name |
N-acetyl-gamma-calicheamicin
|
Payload Info | ||||
| Therapeutic Target |
Human deoxyribonucleic acid (hDNA)
|
Target Info | ||||
| Linker Name |
Mc-PEG8-acid-labile linker
|
Linker Info | ||||
| Conjugate Type |
Reactive Cysteines
|
|||||
| Special Approval(s) |
Orphan drug (EMA)
|
|||||
The indication landscape of This ADC(2027 Update)
The clinical trial pipeline of This ADC(2027 Update)
| Indication | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | New Drug Application | Approved | ||
|---|---|---|---|---|---|---|---|---|---|
| Lung cancer |
1 Trials
|
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Discovered Using Patient-derived Xenograft Model
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Objective Response Rate (ORR) |
25%
|
|||
| Patients Enrolled |
Eligible participants have relapsed/refractory SCLC (1-3 prior lines), measurable disease (RECIST v1.1), ECOG 0-1, and adequate organ function. Key exclusions: cirrhosis, cardiac disease (>6 months prior), active infections, autoimmune/neurologic conditions, or hypersensitivity to study drugs. SEZ6+ tumor tissue is required for Parts B/C. Additional exclusions for Part C include neuropathy ≥G2, IBD, or prior anti-PD-1/PD-L1 with unresolved irAEs.
Click to Show/Hide
|
||||
| Administration Dosage |
ABBV-011 was administered intravenously at doses from 0.3 to 2.0 mg/kg once every 3 weeks. Dose expansion was conducted in SEZ6-selected patients.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT03639194 | Clinical Status | PHASE1 | ||
| Clinical Description | A Phase I Study of ABBV-011 as a Single-Agent and in Combination With Budigalimab (ABBV-181) in Subjects With Relapsed or Refractory Small Cell Lung Cancer | ||||
| Primary Endpoint |
The study evaluates AEs, SAEs, DLTs, and determines MTD/RP2D for ABBV-011 alone and in combination with budigalimab over ~5 years, alongside monitoring vital signs, lab abnormalities, and ECG changes.
|
||||
| Other Endpoint |
PK parameters (Cmax, AUC, Tmax, T1/2, etc.) and immunogenicity (ADA) for ABBV-011 are assessed. Efficacy endpoints include ORR, CBR, DOR, DOCB, PFS, and OS per RECIST v1.1 over ~5 years.
|
||||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Clinical benefit rate (CBR) |
64%
|
|||
| Patients Enrolled |
Eligible participants have relapsed/refractory SCLC (1-3 prior lines), measurable disease (RECIST v1.1), ECOG 0-1, and adequate organ function. Key exclusions: cirrhosis, cardiac disease (>6 months prior), active infections, autoimmune/neurologic conditions, or hypersensitivity to study drugs. SEZ6+ tumor tissue is required for Parts B/C. Additional exclusions for Part C include neuropathy ≥G2, IBD, or prior anti-PD-1/PD-L1 with unresolved irAEs.
Click to Show/Hide
|
||||
| Administration Dosage |
ABBV-011 was administered intravenously at doses from 0.3 to 2.0 mg/kg once every 3 weeks. Dose expansion was conducted in SEZ6-selected patients.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT03639194 | Clinical Status | PHASE1 | ||
| Clinical Description | A Phase I Study of ABBV-011 as a Single-Agent and in Combination With Budigalimab (ABBV-181) in Subjects With Relapsed or Refractory Small Cell Lung Cancer | ||||
| Primary Endpoint |
The study evaluates AEs, SAEs, DLTs, and determines MTD/RP2D for ABBV-011 alone and in combination with budigalimab over ~5 years, alongside monitoring vital signs, lab abnormalities, and ECG changes.
|
||||
| Other Endpoint |
PK parameters (Cmax, AUC, Tmax, T1/2, etc.) and immunogenicity (ADA) for ABBV-011 are assessed. Efficacy endpoints include ORR, CBR, DOR, DOCB, PFS, and OS per RECIST v1.1 over ~5 years.
|
||||
| Experiment 3 Reporting the Activity Date of This ADC | [2] | ||||
| Related Clinical Trial | |||||
| NCT Number | NCT03639194 | Clinical Status | Phase 1 | ||
| Clinical Description | A phase 1 study of ABBV-011 as a single-agent and in combination with budigalimab (ABBV-181) in subjects with relapsed or refractory small cell lung cancer. | ||||
Discovered Using Patient-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 15.30% | Positive SEZ6 expression (SEZ6+++/++) | ||
| Method Description |
ABBV-011 LD(NAC-LD19.10)=0.24 mg/kg.
|
||||
| In Vivo Model | SCLC PDX model (PDX: LU64) | ||||
| Experiment 2 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 35.60% | Positive SEZ6 expression (SEZ6+++/++) | ||
| Method Description |
ABBV-011 induces efficient tumor cell killing in cell line-derived models of LU64 and LU149 cells with SC17 expression with high expression.
|
||||
| In Vivo Model | Small cell lung cancer PDX model (PDX: LU149) | ||||
| Experiment 3 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 42.85% | Negative SEZ6 expression (SEZ6-) | ||
| Method Description |
ABBV-011 induces efficient tumor cell killing in cell line-derived models of LU64 and LU149 cells with SC17 expression with high expression.
|
||||
| In Vivo Model | Small cell lung cancer PDX model (PDX: LU505) | ||||
| Experiment 4 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 45.90% | Positive SEZ6 expression (SEZ6+++/++) | ||
| Method Description |
ABBV-011 ADC=8mg/kg.
|
||||
| In Vivo Model | SCLC PDX model (PDX: LU505) | ||||
| Experiment 5 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 71.70% | Positive SEZ6 expression (SEZ6+++/++) | ||
| Method Description |
ABBV-011 ADC=1 mg/kg.
|
||||
| In Vivo Model | SCLC PDX model (PDX: LU149) | ||||
| Experiment 6 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 87% | Positive SEZ6 expression (SEZ6+++/++) | ||
| Method Description |
NAC-LD19.10 ADC=8mg/kg.
|
||||
| In Vivo Model | SCLC PDX model (PDX: LU505) | ||||
| Experiment 7 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 89.80% | Positive SEZ6 expression (SEZ6+++/++) | ||
| Method Description |
ABBV-011 ADC=1 mg/kg.
|
||||
| In Vivo Model | SCLC PDX model (PDX: LU95) | ||||
| Experiment 8 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 89.80% | Positive SEZ6 expression (SEZ6+++/++) | ||
| Method Description |
ABBV-011 induces efficient tumor cell killing in cell line-derived models of LU64 and LU149 cells with SC17 expression with high expression.
|
||||
| In Vivo Model | Small cell lung cancer PDX model (PDX: LU149) | ||||
| Experiment 9 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 92% | Positive SEZ6 expression (SEZ6+++/++) | ||
| Method Description |
ABBV-011 ADC=0.5 mg/kg.
|
||||
| In Vivo Model | SCLC PDX model (PDX: LU64) | ||||
| Experiment 10 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 93.50% | Positive SEZ6 expression (SEZ6+++/++) | ||
| Method Description |
ABBV-011 ADC=2 mg/kg.
|
||||
| In Vivo Model | SCLC PDX model (PDX: LU149) | ||||
| Experiment 11 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 94.78% | Positive SEZ6 expression (SEZ6+++/++) | ||
| Method Description |
ABBV-011 induces efficient tumor cell killing in cell line-derived models of LU64 and LU149 cells with SC17 expression with high expression.
|
||||
| In Vivo Model | Small cell lung cancer PDX model (PDX: LU95) | ||||
| Experiment 12 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 96% | Positive SEZ6 expression (SEZ6+++/++) | ||
| Method Description |
ABBV-011 induces efficient tumor cell killing in cell line-derived models of LU64 and LU149 cells with SC17 expression with high expression.
|
||||
| In Vivo Model | Small cell lung cancer PDX model (PDX: LU64) | ||||
| Experiment 13 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 96.80% | Positive SEZ6 expression (SEZ6+++/++) | ||
| Method Description |
ABBV-011 ADC=2 mg/kg.
|
||||
| In Vivo Model | SCLC PDX model (PDX: LU95) | ||||
| Experiment 14 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 97% | Positive SEZ6 expression (SEZ6+++/++) | ||
| Method Description |
ABBV-011 ADC=4 mg/kg.
|
||||
| In Vivo Model | SCLC PDX model (PDX: LU95) | ||||
| Experiment 15 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 98% | Positive SEZ6 expression (SEZ6+++/++) | ||
| Method Description |
ABBV-011 ADC=1 mg/kg.
|
||||
| In Vivo Model | SCLC PDX model (PDX: LU64) | ||||
| Experiment 16 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 98.40% | Positive SEZ6 expression (SEZ6+++/++) | ||
| Method Description |
ABBV-011 ADC=2 mg/kg.
|
||||
| In Vivo Model | SCLC PDX model (PDX: LU64) | ||||
| Experiment 17 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 98.70% | Positive SEZ6 expression (SEZ6+++/++) | ||
| Method Description |
ABBV-011 ADC=4 mg/kg.
|
||||
| In Vivo Model | SCLC PDX model (PDX: LU149) | ||||
| Experiment 18 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 99.60% | Positive SEZ6 expression (SEZ6+++/++) | ||
| Method Description |
ABBV-011 induces efficient tumor cell killing in cell line-derived models of LU64 and LU149 cells with SC17 expression with high expression.
|
||||
| In Vivo Model | Small cell lung cancer PDX model (PDX: LU95) | ||||
| Experiment 19 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 99.80% | Positive SEZ6 expression (SEZ6+++/++) | ||
| Method Description |
ABBV-011 induces efficient tumor cell killing in cell line-derived models of LU64 and LU149 cells with SC17 expression with high expression.
|
||||
| In Vivo Model | Small cell lung cancer PDX model (PDX: LU95) | ||||
| Experiment 20 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 100% | Positive SEZ6 expression (SEZ6+++/++) | ||
| Method Description |
ABBV-011 induces efficient tumor cell killing in cell line-derived models of LU64 and LU149 cells with SC17 expression with high expression.
|
||||
| In Vivo Model | Small cell lung cancer PDX model (PDX: LU149) | ||||
| Experiment 21 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 100% | Positive SEZ6 expression (SEZ6+++/++) | ||
| Method Description |
ABBV-011 induces efficient tumor cell killing in cell line-derived models of LU64 and LU149 cells with SC17 expression with high expression.
|
||||
| In Vivo Model | Small cell lung cancer PDX model (PDX: LU64) | ||||
| Experiment 22 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 100% | Positive SEZ6 expression (SEZ6+++/++) | ||
| Method Description |
ABBV-011 induces efficient tumor cell killing in cell line-derived models of LU64 and LU149 cells with SC17 expression with high expression.
|
||||
| In Vivo Model | Small cell lung cancer PDX model (PDX: LU64) | ||||
References